Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.
The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.
One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.
Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.
Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.
For more information, please visit their website at www.ternspharma.com.
Terns Pharmaceuticals has appointed Dr. Ann E. Taylor to its Board of Directors. With over 35 years in drug development, including her tenure as Chief Medical Officer at AstraZeneca, Dr. Taylor is expected to bring valuable expertise to Terns, particularly in developing treatments for non-alcoholic steatohepatitis (NASH) and chronic liver diseases. Terns is known for its innovative therapeutic approaches, including a diverse pipeline featuring small-molecule therapies aimed at addressing NASH.
Terns Pharmaceuticals has completed patient enrollment for Part 1 of the AVIATION Trial, a Phase 1b study for TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH patients. Preliminary top-line data is expected in 1Q 2022. The trial aims to assess the safety and tolerability of TERN-201 in comparison to a placebo over 12 weeks. TERN-201 has shown promise in preclinical studies, and the company received FDA Fast Track Designation for the treatment of NASH.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on therapies for non-alcoholic steatohepatitis (NASH), announced upcoming presentations at key investor conferences in September 2021. The conferences include the 2021 Virtual Wells Fargo Healthcare Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Summit on September 20. Investors can access live webcasts on Terns' investor relations page, with replays available for 30 days.
Terns Pharmaceuticals reported financial results for Q2 2021, achieving significant clinical milestones in its NASH pipeline. The company initiated the Phase 1b AVIATION Trial for TERN-201 and completed a multiple ascending dose portion of the TERN-501 trial. Cash reserves are strong at $185.1 million, projected to last until 2024. Top-line data from TERN-501 is expected in 4Q 2021 and from TERN-201 in 1H 2022. Despite a net loss of $10.7 million for the quarter, decreased R&D expenses show a positive trend for operating efficiency.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced its participation in two key healthcare conferences. Management will join a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on August 10 at 2:20 PM ET. Additionally, Terns will present at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 1:00 PM ET. Both events will be available via live webcast on Terns' investor relations page, with replays accessible for 30 days post-presentation.
Terns Pharmaceuticals initiated patient dosing for the AVIATION Trial, a Phase 1b study evaluating TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH. This trial aims to assess the safety and efficacy of TERN-201 over a 12-week period, with preliminary data expected in 2022. TERN-201 demonstrated well-tolerated results in prior studies, showing significant potential in reducing liver inflammation. The drug's selective inhibition may complement other therapies in Terns’ portfolio.
Terns Pharmaceuticals reported positive results from the Phase 2a LIFT clinical trial of TERN-101, an FXR agonist for NASH treatment. The trial demonstrated no discontinuations due to adverse events, including pruritus, and significant improvements in corrected T1 (cT1), a liver inflammation and fibrosis marker. After 12 weeks, significant changes in cT1 were observed in the 10 mg and 15 mg groups compared to placebo. Terns plans a combination trial of TERN-101 with TERN-501 in early 2022, following these promising outcomes.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.
Terns Pharmaceuticals is set to present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET, followed by participation in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET. A live audio webcast will be accessible on the company’s investor page, with a 30-day archive available post-event. Terns specializes in developing small-molecule therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. For more details, visit their official website.
Terns Pharmaceuticals reported Q1 2021 financial results and corporate updates, highlighting advancements in their NASH clinical programs. With top-line data for the Phase 2a LIFT study of TERN-101 expected in June 2021, the company emphasizes the focus on safety and multiple non-invasive endpoints. The oversubscribed IPO raised $147 million, enhancing their financial position. R&D expenses rose to $8.7 million, while the net loss increased to $13.3 million from $9.2 million a year earlier. Cash reserves of $195.6 million are projected to support operations through 2024.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
What does Terns Pharmaceuticals, Inc. specialize in?
Where is Terns Pharmaceuticals located?
What is TERN-501 and what disease does it target?
What are the main therapeutic areas Terns Pharmaceuticals focuses on?
What is the significance of TERN-701?
How is Terns Pharmaceuticals funded for its operations?
What recent achievement has Terns Pharmaceuticals made in clinical trials?
What is TERN-601 being developed for?
What is the main objective of Terns Pharmaceuticals?
Where can I find more information about Terns Pharmaceuticals' research and development activities?
